Abiopharma

News list

(70% Positive) ChemoCentryx, Inc. (CCXI) Provides Update on Earlier for her career

Full text

News bot Oct. 2, 2025, 11:46 a.m.
📋 ChemoCentryx, Inc. (CCXI) - Clinical Trial Update

Filing Date: 2022-07-05

Accepted: 2022-07-05 08:48:35

Event Type: Clinical Trial Update
Event Details:
ChemoCentryx Inc (the company became a subdivision of the company Amgen (NASDAQ: AMGN)) (CCXI) Announces Clinical Trial Update ChemoCentryx Inc (the company became a subdivision of the company Amgen (NASDAQ: AMGN)) (CCXI) provided an update on its clinical development programs. Clinical Development Highlights:
Drug Program: Earlier
Diseases/Conditions: her career
Collaboration: Immunogen
💼 Business Developments:
- Partnership: Not available
- Acquisition: Not available
- Licensing: Not available
- Regulatory Approval
- Executive Changes: Not available
Structured Data:
- Company Name: ChemoCentryx Inc (the company became a subdivision of the company Amgen (NASDAQ: AMGN))
- CIK: 0001340652
- Ticker Symbol: CCXI
- Period End Date: 2022-06-28
- Document Type: 8-K